clinical trial · NCT06528314
A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
Akero Therapeutics, Inc·phase3·recruiting·n = 2,150
NASH - Nonalcoholic SteatohepatitisMASH - Metabolic Dysfunction-Associated SteatohepatitisEfruxiferminPlacebo
brief summary
This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.
started
Sep 4, 2024
primary completion
Feb 1, 2030
completion
Mar 1, 2030
last updated
Jun 8, 2026
official title
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study Evaluating the Safety and Efficacy of Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol